Drug Development Process


Introduction to Drug Development Process

- The drug development process is a highly structured, multidisciplinary, and strictly regulated pathway that transforms a basic scientific discovery—such as a new chemical entity (NCE) or biologically active compound—into a safe, effective, and marketable pharmaceutical product.
- This journey encompasses scientific research, preclinical studies, clinical trials, and regulatory approvals, all under the oversight of national and international regulatory authorities such as the FDA (United States), EMA (Europe), and CDSCO (India).

Key Characteristics

- **Timeframe**: Typically, 10–15 years
- **Cost**: Can exceed billions of dollars
- **Primary Objectives**:
  - Establish safety (minimal toxicity)
  - Demonstrate efficacy (therapeutic benefit)
  - Ensure stability and reproducibility of the dosage form
  - Achieve compliance with regulatory standards

Phases of Drug Development



1. Drug Discovery & Target Identification

- Involves identifying disease-related biological targets, such as enzymes, receptors, or genetic pathways.
- Utilizes techniques like high-throughput screening (HTS), computational drug design, or natural product screening to discover lead compounds.
- Followed by lead optimization to improve activity, reduce toxicity, and refine pharmacokinetic properties.

2. Preclinical Development

- Conducted in **in vitro** (e.g., cell cultures) and **in vivo** (animal model) settings.
- Aims to determine:
  - **Pharmacodynamics (PD)**: mechanism of drug action
  - **Pharmacokinetics (PK)**: absorption, distribution, metabolism, excretion (ADME)
  - **Toxicological profiles**: acute, sub-acute, chronic, genotoxicity, carcinogenicity
- Provides data required for Investigational New Drug (IND) application.

3. IND Submission (Investigational New Drug Application)

- Submitted to regulatory bodies (e.g., FDA) before human testing.
- **Must include:**
  - Detailed preclinical results
  - Manufacturing information
  - Clinical study protocols
  - Investigator and institutional qualifications

4. Clinical Trials

- Clinical studies are conducted in **three major phases**:

A. Phase I:

- **Focus**: Safety, dosage, and tolerability
- **Subjects**: 20–100 healthy volunteers
- **Outcome**: Initial pharmacokinetic and pharmacodynamic profile

B. Phase II:

- **Focus**: Therapeutic efficacy and side effects
- **Subjects**: 100–300 patients
- **Outcome**: Optimal dosing regimen and therapeutic potential

C. Phase III:

- **Focus**: Confirm efficacy and monitor adverse effects on a large scale
- **Subjects**: 1,000–3,000+ patients
- **Outcome**: Data for regulatory submission (NDA)

5. NDA Submission (New Drug Application)

- A comprehensive document submitted to regulatory authorities after Phase III trials.
- Includes:

- All clinical and non-clinical data
- Chemistry, Manufacturing, and Controls (CMC)
- Labeling and usage instructions

➢ Subject to detailed review for approval or rejection.

6. Regulatory Approval & Post-Marketing Surveillance (Phase IV)

➢ Upon approval, the drug enters the market.

➢ **Phase IV** involves:

- Ongoing surveillance for long-term safety and efficacy
- Detection of rare or unexpected adverse events
- Real-world data collection that may lead to changes in labeling, restrictions, or withdrawal

Various Approaches to drug discovery

Pharmacological Approach to Drug Discovery

Definition

- The pharmacological approach involves identifying and studying the effects of chemical substances on biological systems, particularly to find compounds that can modify a disease process through a specific biological target (like a protein, enzyme, or receptor).
- This approach is often grounded in understanding the pathophysiology of a disease and finding a drug that can intervene at a key biological point.

Key Considerations

- Specificity of binding
- Potency and efficacy
- Reversibility of interaction
- ADME properties (Absorption, Distribution, Metabolism, and Excretion)

Key Steps in the Pharmacological Approach

1. **Target Identification and Validation**
   - Involves discovering a biological molecule (e.g., a receptor or enzyme) that plays a critical role in the disease.
   - Validation confirms that this target is relevant and "druggable" (can interact with a therapeutic compound).
2. **Lead Compound Identification**
   - Through **high-throughput screening (HTS)** or computational methods (in silico), thousands to millions of compounds are tested for activity against the target.
   - The most promising hits are selected as **lead compounds**.
3. **Mechanism of Action Studies**
   - Investigate how the lead compound works at the molecular level.
   - Studies include receptor binding, enzyme inhibition, signal transduction, etc.
4. **In Vitro Pharmacology**
   - Tests conducted in cell cultures or isolated tissues to determine the pharmacological profile (agonist, antagonist, partial agonist, etc.) of the compound.
   - Determines potency (EC50 or IC50), selectivity, and efficacy.
5. **In Vivo Pharmacology**
   - Animal models are used to study pharmacodynamic (PD) effects.

- Helps to understand the drug's effect in a living system and its potential therapeutic value.

6. Structure-Activity Relationship (SAR) Studies

- Chemical modifications are made to optimize activity.
- Understanding how changes in molecular structure affect biological activity helps refine potency and reduce side effects.

7. Pharmacokinetics and Pharmacodynamics (PK/PD)

- Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME).
- Pharmacodynamics: Relationship between drug concentration and effect.

Advantages of Pharmacological Approach

- Direct insight into biological effect.
- Clear linkage between drug action and disease modification.
- Early detection of therapeutic and adverse effects.

Limitations

- Complex diseases may not have a single target.
- Results in animals may not translate to humans.
- High cost and time-consuming.

Toxicological Approach to Drug Discovery

Definition:

- The toxicological approach in drug development focuses on identifying and understanding the potential harmful effects of a drug candidate. This includes evaluating the compound's safety profile before it enters human trials.
- Toxicological studies are typically part of the preclinical phase, but toxicity considerations also guide early-stage compound selection and optimization.

Objectives of Toxicological Studies:

1. Determine the Safety Margin

- Identify the maximum tolerated dose (MTD).
- Establish the no observed adverse effect level (NOAEL).

2. Characterize Toxic Effects

- Evaluate organ-specific toxicity (liver, kidney, heart, etc.).
- Assess acute, sub-chronic, and chronic toxicity.

First Hope

FREE PREVIEW

Click here to visit our website

PHARMACY PREMIUM NOTES

Complete subject and semesters are available on FirstHope app only.

Scan or click here

Click here to get the app >

Available on Google Play

JOIN THE FIRSTHOPE COMMUNITY

Join our Telegram channel

Click here to join Telegram >

Scan or click here

@FirstHopeNotes

Instagram

@firsthope.official

Click here to follow >

YouTube channel

FirstHope-Pharmacy / Live streams

Click here to watch >

WhatsApp channel

Follow FirstHope on WhatsApp

Click here to join >

FirstHope website

firsthope.co.in

Click here to visit >

B.Pharm / D.Pharm / M.Pharm / Pharm.D

Preview notes. Complete subjects and semesters in the FirstHope app.